VECTURA
LIVE

Serial Number

98217245

Owner

Vectura Limited

Attorney

Molly B. Markley

Filing Date

Oct 10, 2023

Add to watchlist:

No watchlists yet
View on USPTO

VECTURA Trademark

Serial Number: 98217245 • Registration: 8248997

VECTURA is a trademark filed by Vectura Limited on October 10, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Vectura Limited (17 trademarks)

1 Prospect West
Chippenham, Wiltshire SN146FH , GB

Entity Type: 99

Trademark Details

Filing Date

October 10, 2023

Registration Date

May 12, 2026

Published for Opposition

March 24, 2026

Goods & Services

Surgical, medical, and veterinary apparatus, instruments and parts and fittings therefor, namely, drug delivery devices and parts and fittings therefor, namely, drug delivery systems being nebulizers for medical purposes; inhalers sold empty for medical or therapeutic purposes and parts and fittings therefor; active dry powder inhalers sold empty for medical or therapeutic purposes and parts and fittings therefor; passive dry powder inhalers sold empty for medical or therapeutic purposes and parts and fittings therefor; nebulisers for inhalation therapy, namely, respiration therapy, and parts and fittings therefor; inhaler devices sold empty for medical or therapeutic purposes and parts and fittings therefor; all of the above goods not for use in the dental field

Custom manufacture of pharmaceuticals; Consulting services in the field of pharmaceutical formulation, development of medical applications for drugs and pharmaceutical formulations, drug design, drug formulation, pharmaceutical formulation, and development of pharmaceutical formulations

Scientific research and technological services, namely, research, design, analysis, and testing, in the field of pharmaceuticals and drug delivery systems, and drug delivery systems and devices; Scientific research and technological services, namely, research in the field of medicine; industrial analysis and research services in the fields of drug delivery systems and devices; research services in the fields of medicine; pharmaceutical research services; pharmaceutical products development services; device and product safety testing services;

Pharmaceutical and veterinary preparations for the treatment of diseases or conditions of the respiratory system; pharmaceutical and veterinary preparations for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynaecological conditions; pharmaceutical and veterinary preparations for the alleviation or prevention of pain or inflammation; inhalers filled with powders for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynaecological conditions; pharmaceutical preparations, namely, powders for asthma inhalers; pharmaceutical preparations, namely, powders for transdermal injection for the alleviation or prevention of pain, for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for oral ingestion for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for topical administration for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; medicaments for inhalation therapy; pharmaceutical preparations, namely, pulmonary delivery compositions for use in facilitating the inhalation of pharmaceuticals, namely, drug delivery agents consisting of compounds that facilitate delivery by inhalation of a wide range of pharmaceuticals; medicaments for the treatment of erectile dysfunction; medicaments for the treatment of chronic obstructive pulmonary disease; medicaments for the treatment of premature ejaculation; medicaments for the treatment of cystic fibrosis; medicaments for the treatment of female sexual dysfunction; medicaments for the treatment of migraines; medicaments for the treatment of asthma; all of the above goods not for use in the dental field

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 12, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
May 12, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 24, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 24, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 18, 2026 NONP
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Feb 27, 2026 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 23, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 19, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 19, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 19, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 22, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jan 22, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jan 22, 2026 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jan 22, 2026 ZZZX
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Jan 16, 2026 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 8, 2026 CNSA
ATTORNEY REVIEW COMPLETED
Jan 8, 2026 ATRV
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Apr 21, 2025 ZZZX
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Sep 12, 2024 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 9, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 6, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 6, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 6, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 10, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jun 10, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jun 10, 2024 CNRT
ASSIGNED TO EXAMINER
May 29, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 16, 2023 NWOS
NEW APPLICATION ENTERED
Oct 13, 2023 NWAP